We asked venture capitalists what startups they wish they could fund. Many had an interest in finding companies that could tackle neurodegenerative diseases, including Alzheimer's, though not much has caught their eyes so far. "The problem...Show More Summary
There are signs from past years to suggest that Alzheimer's disease is a reversible condition, at least in its earlier stages. In other words, that there is little loss of the structures holding the data of the mind, and the condition degrades the operation of the mind, not its underpinnings. Show More Summary
Old dogs can have a version of Alzheimer's disease and data suggests that this might be prevented by changing what they eat
New findings could change how iron metabolism in the human body is understood, and open new horizons for research and therapeutics for inflammatory diseases and neurodegenerative diseases, such as Alzheimer's and Parkinson's disease...
(McGill University) Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint French and Canadian study published in Scientific Reports now challenges this view.
At a panel discussion this week in Sacramento, patients, caregivers and others shared their perspectives on how Alzheimer’s disease affects women, who account for two-thirds of those living with the condition.
Anxiety symptoms could be a warning sign of Alzheimer's disease years before any symptoms of impairment are noticed, a new study found
The degenerative processes behind Alzheimer's disease have been found to begin 10, or even 20 years before dementia symptoms become evident and the condition is diagnosed. A new study suggests that increasing symptoms of anxiety could...Show More Summary
New research has linked increasing symptoms of anxiety in older adults to higher brain levels of beta-amyloid, a protein linked to Alzheimer's disease.
(Brigham and Women's Hospital) A new study suggests an association between elevated amyloid beta levels & the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of Alzheimer's disease in older adults.
The financial and social costs of neurological diseases such as Alzheimer’s are devastating. It’s essential that big pharma be part of the effort to end them If you were to go out on the street today and run a straw poll on big pharma, I doubt that it would come back very positive. Show More Summary
Absent any greater context on Alzheimer's disease research, one might look back at the past twenty years of clinical trials and consider this medical condition to be an insurmountable obstacle at our present stage of progress in biotechnology. Show More Summary
In a move that will cost approximately 300 people their jobs, Pfizer’s $19 million a year CEO Ian Read shut down his company’s research into cures for Alzheimer’s and Parkinson’s Disease. In a statement sent to NPR, Pfizer officialsShow More Summary
Alzheimer's is a devastating disease, and with the world's average population getting older, its effects will be felt further and wider in the future. A drug dubbed J147, developed by the Salk Institute, is one of the most promising candidates to treat Alzheimer's, but just how it worked at the molecular level remained a mystery. Show More Summary
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer’s disease and come up short, we can now add three more. An experimental drug called idalopirdine failed to help people with mild to moderate Alzheimer’s disease in a trio of trials that involved 2,525...
(Case Western Reserve University) Researchers from Case Western Reserve University School of Medicine and collaborators have received a five-year, $2.8 million grant from the National Institute on Aging to identify FDA-approved medications that could be repurposed to treat Alzheimer's disease. Show More Summary
Disappointment as idalopirdine fails at trial to improve cognition and limit decline in patients with mild to moderate Alzheimer’s disease The quest to develop drugs to treat Alzheimer’s disease has experienced a new setback, with a promising medication failing to show benefits in the latest series of clinical trials. Show More Summary
(Salk Institute) Salk researchers identify the molecular target of J147, which is nearing clinical trials to treat Alzheimer's disease.
The experimental drug J147 is something of a modern elixir of life; it's been shown to treat Alzheimer's disease and reverse aging in mice and is almost ready for clinical trials in humans. Now scientists have solved the puzzle of what, exactly, J147 does. Show More Summary